Brief: GlycoMimetics Inc Says NCI-Sponsored Trial Of Uproleselan In Older, Newly Diagnosed AML Patients Fit For Intensive Chemotherapy Completes Enrollment Of Phase 2 Portion Ahead Of Schedule
06/12/2021 14:16
Dec 6 (Reuters) - GlycoMimetics Inc GLYC.O :
* NCI-SPONSORED TRIAL OF UPROLESELAN IN OLDER, NEWLY
DIAGNOSED AML
PATIENTS FIT FOR INTENSIVE CHEMOTHERAPY COMPLETES ENROLLMENT OF
PHASE 2 PORTION AHEAD OF SCHEDULE
Source text for Eikon: ID:nBw6Qtsgra
Further company coverage: GLYC.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering